Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 0.5 ml - injection, solution - excipient ingredients: - revestive is indicated for the treatment of adult and paediatric patients 2 years of age and above with short bowel syndrome (sbs) who are dependent on parenteral support.,patients should be stable for at least 4 weeks on their parenteral support regimen before initiating teduglutide therapy

Kenya - inglise - Pharmacy and Poisons Board

galpha laboratories ltd galpha laboratories ltd - ceftriaxone powder for injection 1gm - injection - ceftriaxone powder for injection 1gm - antiinfectives for systemic use

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lincomycin hydrochloride monohydrate, quantity: 680.4 mg (equivalent: lincomycin, qty 600 mg) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - lincomycin sxp is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with lincomycin injection therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see precautions).,the specific infections for which lincomycin sxp is indicated are as follows:,upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.,lower respiratory infections including acute and chronic bronchitis and pneumonia.,skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,bone and joint infections including osteomyelitis and septic arthritis.,septicaemia and endocarditis. selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. however, bactericidal drugs are often preferred for these infections.,bacillary dysentery. although shigella is resistant to lincomycin in vitro (mic approximately 200-400 micrograms/ml), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lincomycin hydrochloride monohydrate, quantity: 340.2 mg (equivalent: lincomycin, qty 300 mg) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - lincomycin sxp is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with lincomycin injection therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see precautions).,the specific infections for which lincomycin sxp is indicated are as follows:,upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.,lower respiratory infections including acute and chronic bronchitis and pneumonia.,skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,bone and joint infections including osteomyelitis and septic arthritis.,septicaemia and endocarditis. selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. however, bactericidal drugs are often preferred for these infections.,bacillary dysentery. although shigella is resistant to lincomycin in vitro (mic approximately 200-400 micrograms/ml), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

takeda new zealand limited - teduglutide 5mg; water for injection 0.5 ml - powder for injection with diluent - 5 mg - active: teduglutide 5mg excipient: dibasic sodium phosphate heptahydrate histidine hydrochloric acid mannitol monobasic sodium phosphate monohydrate sodium hydroxide water for injection active: water for injection 0.5 ml - revestive is indicated for the treatment of adult patients with short bowel syndrome (sbs) who are dependent on parenteral support. patients should be stable at least to 4 weeks on their parenteral support regimen before initiating teduglutide therapy

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - water for injections, quantity: 10 ml - injection, solvent for - excipient ingredients: - water for injections is used for the reconstitution and preparation of aqueous injections

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - water for injections, quantity: 20 ml - injection, solvent for - excipient ingredients: - water for injections is used for the reconstitution and preparation of aqueous injections

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - water for injections, quantity: 250 ml - injection, solvent for - excipient ingredients: - water for injections is used for the reconstitution and preparation of aqueous injections

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - water for injections, quantity: 1000 ml - injection, solvent for - excipient ingredients: - water for injections is used for the reconstitution and preparation of aqueous injections

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - water for injections, quantity: 100 ml - injection, solvent for - excipient ingredients: - water for injections is used for the reconstitution and preparation of aqueous injections